Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a research note published on Monday morning, MarketBeat ...

Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...

Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...

EXCLUSIVE: The parents of two siblings with a life-limiting condition are waiting in agony to find out if health chiefs will ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.